Press Release – New York, NY – January 15, 2026 – Sichenzia Ross Ference Carmel LLP announced today that it represented BriaCell Therapeutics Corp. (NASDAQ: BCTX, BCTXL) (TSX: BCT), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, in its $30 million public offering.
The SRFC team was led by partners Gregory Sichenzia, Jeff Cahlon and Avital Perlman, with associates Christian Lichtenberger and Benasz Hansotia.